The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
Official Title: A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Study ID: NCT02549651
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
Detailed Description: This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 (durvalumab) as monotherapy or in combination with either tremelimumab or AZD9150. The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, La Jolla, California, United States
Research Site, Baltimore, Maryland, United States
Research Site, Albuquerque, New Mexico, United States
Research Site, Durham, North Carolina, United States
Research Site, Charleston, South Carolina, United States
Research Site, Dallas, Texas, United States
Research Site, Houston, Texas, United States
Research Site, Milwaukee, Wisconsin, United States
Research Site, Marseille, , France
Research Site, Villejuif, , France
Research Site, Dublin 8, , Ireland
Research Site, Galway, , Ireland
Research Site, Leicester, , United Kingdom
Name: MedImmune LLC
Affiliation: MedImmune LLC
Role: STUDY_DIRECTOR